Analysis Connect Biopharma Holdings Limited (CNTB)
5/31/2024
Analysis of Connect Biopharma Holdings Limited (CNTB)
Connect Biopharma Holdings Limited (CNTB) has been showing some volatility in its stock price recently. The Relative Strength Index (RSI) values have been fluctuating around the mid-range, indicating a lack of strong trend in the stock. The Moving Average Convergence Divergence (MACD) indicator has been hovering around the zero line, suggesting a balance between buying and selling pressure.Looking at the Moving Averages (MA), the stock price has been trading below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) in the recent days. This could indicate a short-term bearish sentiment in the stock.
Overall, based on the technical indicators, CNTB appears to be in a consolidation phase with no clear trend direction. Traders and investors may want to wait for more definitive signals before making any significant trading decisions.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. The operating cash flow has been increasing steadily from 2020 to 2023, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
5. Financing activities show significant changes each year, with fluctuations in common dividends, stock repurchases, and debt issuances.
6. Investing activities also vary, with notable amounts spent on acquisitions, investments, and capital expenditures.
7. Overall, the company's financial performance seems to be dynamic, with changes in cash flow driven by operational, financing, and investing activities.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, which is higher than the EPS of $1.26 from the same quarter a year ago. The range of estimates is between $1.27 and $1.36, as provided by 26 analysts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 from the previous year's quarter. The estimates range from $1.44 to $1.63, based on 25 analysts' forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, an increase from the previous year's EPS of $6.13. The analysts' estimates range from $6.43 to $6.92, with insights from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is projected to be $7.23, with a range of estimates between $6.40 and $7.90. This forecast is based on inputs from 39 analysts.
Overall, the trend indicates a growth in earnings per share both quarterly and annually, reflecting positive expectations from analysts regarding the company's performance in the upcoming periods.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year.
- The growth rate is projected to increase to 5.6% in the current quarter and further to 4.8% in the next quarter.
- Over the next year, the growth rate is expected to reach 9.7%.
- Looking ahead, the company is forecasted to achieve an annual growth rate of 11% over the next 5 years.
- However, when comparing to the past 5 years, where the company had a growth rate of 20.15% per annum, the future growth rate is expected to be lower.
Overall, the company is expected to maintain a positive growth trajectory, with a slight decrease in growth rate compared to the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is $191.57, which is below the average and median forecast. Investors should consider these different price targets and the current price when making decisions about buying or selling the security.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for the quarter ending on October 31, 2024, were not provided on time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit margin: 26.306%
- Fiscal year ends: September 30, 2023
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%
- Most recent quarter: March 31, 2024
- Return on assets TTM: 22.073999%
- Return on equity TTM: 147.25%
Stock statistics:
- Short ratio: 1.53
- Float shares: 15,308,320,742
- Shares short: 99,287,450
- Average 10-day volume: 46,860,048
- Average 90-day volume: 57,498,254
- Shares outstanding: 15,334,099,968
- Percent held by insiders: 5.22%
- Percent held by institutions: 57.589%
- Short percent of shares outstanding: 0.65%
Valuation metrics:
- PEG ratio: 26.319502
- Forward PE: 26.319502
- Trailing PE: 29.59409
- Enterprise value: $2,950,762,332,160
- Price to book MRQ: 39.3405
- Price to sales TTM: 7.646095
- Enterprise to EBITDA: 22.763
- Enterprise to revenue: 7.732
- Market capitalization: $2,917,925,650,432
Stock price summary:
- Beta: 1.264
- 50-day moving average: $176.2646
- 200-day moving average: $181.0429
- Fifty-two week low: $164.08
- Fifty-two week high: $199.62
- Fifty-two week change: 6.853%
Dividends and splits:
- Payout ratio: 14.93%
- Dividend date: May 16, 2024
- Last split date: August 31, 2020
- Ex-dividend date: May 10, 2024
- Last split factor: 4-for-1 split
- Forward annual dividend rate: $1
- 5-year average dividend yield: 0.73%
- Forward annual dividend yield: 0.5255%
- Trailing annual dividend rate: $0.97
- Trailing annual dividend yield: 0.5097%
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023, showing a healthy growth trajectory.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trend.
7. The company has been able to maintain a stable diluted shares outstanding figure over the years.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving.
MACD of CNTB
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
